SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

Research and Markets: Pediarix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
[April 15, 2014]

Research and Markets: Pediarix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022


DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/zb5v2n/pediarix) has announced the addition of the "Pediarix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022" report to their offering.

Pediarix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine] is GSK's pentavalent combination vaccine that offers protection against infections caused by diphtheria, tetanus, pertussis, three subtypes of poliovirus, and all known subtypes of HBV.

Scope

ul>
  • Overview of Hepatitis B disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Pediarix including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Pediarix for the US from 2012 to 2022.
  • Sales information covered for the US.
  • Reasons to buy

    • Understand and capitalize by identifying products that are most likely to ensure a robust return
    • Stay ahead of the competition by understanding the changing competitive landscape for Hepatitis B
    • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
    • Make more informed business decisions from insightful and in-depth analysis of Pediarix performance
    • Obtain sales forecast for Pediarix from 2012-2022 in the US.

    Key Topics Covered:


    1. Tables & Figures
    2. Introduction
    3. Disease Overview
    4. Vaccination Recommendations and Coverage Rates
    5. Competitive Assessment
    6. Pediarix
    7. Appendix

    For more information visit http://www.researchandmarkets.com/research/zb5v2n/pediarix


    [ Back To TMCnet.com's Homepage ]






    Technology Marketing Corporation

    35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
    Ph: 800-243-6002, 203-852-6800
    Fx: 203-866-3326

    General comments: tmc@tmcnet.com.
    Comments about this site: webmaster@tmcnet.com.

    STAY CURRENT YOUR WAY

    © 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy